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Figure S1: SPR binding assessment of infliximab and FpFinfliximab to recombinant 
human TNF- 
Graphs detailing the Surface Plasmon Resonance (SPR) binding sensograms, 
confirming that infliximab (A) and FpFinfliximab (B) can both bind to human TNF- in a 
concentration-dependent manner. The NTA chip was functionalized with Ni solution 
first and then his-tag TNF-(5𝛍�g/mL) solution prior to loading an anti-TNF- 
molecules (infliximab and FpFinfliximab). 
  
Figure S2 
 
Figure S2: Analysis of retinal infiltrate following infliximab and FpFinfliximab 
treatment 
Groups of immunized mice received intravitreal injection of 15g infliximab or 
FpFinfliximab or vehicle control (EAU) on day 10.  Eyes were enucleated on day 14, and 
retinal infiltrate characterized and quantified.  Graphs detailing the specific CD45+ 
subsets of retinal infiltrate (CD4+, CD8+, CD11b+ and Ly6G+). *P<0.05, **P<0.005, 
***P<0.0005; Data presented as means ± SEM, and representative of two independent 
experiments. 
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Figure S3: Bis-alkylation mechanism to generate three-carbon bridge site-
specific conjugation between Fab and PEG scaffold. 
The mono-sulfones 3 are latently crossed functionalized reagents capable of 
sequential and interactive addition-elimination reactions capable of bis-alkylation. In 
the case of disulfides, first the cysteine thiols are liberated by reduction (e.g. TCEP or 
DTT) and then conjugation involves (i) a first thiol addition to the mono-sulfone reagent 
3, (ii) sulphinic acid elimination to generate a second double bond, and (iii) a second 
thiol addition. 
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Figure S4: B6RPE-07 cell line expression Fcgrt mRNA 
To confirm expression of the neonatal Fc receptor in the B6RPE-07 cell line, Fcgrt 
mRNA levels from 3 separate samples of cultured cells, as well as ex vivo retina and 
cornea tissues were determined by RT-qPCR.  The ex-vivo mouse tissues were 
controls for Fcgrt expression, with retina (postive) and cornea (negative).  Values were 
normalized to Gapdh, and the relative expression (fold change to negative control 
cornea) calculated. 
 
